|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-2-25
|
|
pubmed:abstractText |
Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has single-agent activity in recurrent epithelial ovarian cancer. The primary objective of this phase II study was to characterize the safety and estimate progression-free survival (PFS) of pertuzumab with gemcitabine in patients with platinum-resistant ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/pertuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AmlerLukas CLC,
pubmed-author:DizonDon SDS,
pubmed-author:GlennDanaD,
pubmed-author:GoldMichael AMA,
pubmed-author:JanuarioThomasT,
pubmed-author:KelseyStephenS,
pubmed-author:LinChin-YuCY,
pubmed-author:MakhijaSharmilaS,
pubmed-author:MatulonisUrsulaU,
pubmed-author:NgKimmieK,
pubmed-author:PatonVirginiaV,
pubmed-author:SliwkowskiMark XMX,
pubmed-author:StraussAndreasA,
pubmed-author:UelandFrederick RFR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1215-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19901115-Antibodies, Monoclonal,
pubmed-meshheading:19901115-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19901115-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19901115-Deoxycytidine,
pubmed-meshheading:19901115-Double-Blind Method,
pubmed-meshheading:19901115-Fallopian Tube Neoplasms,
pubmed-meshheading:19901115-Female,
pubmed-meshheading:19901115-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19901115-Humans,
pubmed-meshheading:19901115-Ovarian Neoplasms,
pubmed-meshheading:19901115-Peritoneal Neoplasms,
pubmed-meshheading:19901115-RNA, Messenger,
pubmed-meshheading:19901115-Receptor, erbB-2,
pubmed-meshheading:19901115-Receptor, erbB-3
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
|
|
pubmed:affiliation |
Department of Gynecology and Obstetrics, Emory University School of Medicine, Woodruff Memorial Research Bldg, 1639 Pierce Dr 4305, Atlanta, GA 30322, USA. drmakhija@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
